Dr. Rita Mukhtar sits down for a dialog with Dr. Joshua Sabari to debate the potential use of ctDNA to information breast most cancers remedy: © inventory.adobe.com.
The power to make use of circulating tumor DNA (ctDNA) to information surgical decision-making following neoadjuvant chemotherapy was explored in a presentation by researchers on the 2025 ASCO Annual Assembly.
In an interview following the assembly, Dr. Rita Mukhtar, one of many trial investigators, sat down for an interview with Dr. Joshua Ok. Sabari, editor-in-chief of CURE, to additional discover ctDNA on this house. ctDNA are small items of DNA which could be detected and are launched by tumor cells into an individual’s blood; if detected early, they’ve the potential to information therapy choices, in keeping with the Nationwide Most cancers Institute web site.
Mukhtar focuses on breast and normal surgical procedure and serves as an affiliate professor of surgical procedure within the Division of Surgical Oncology on the College of San Francisco (UCSF), UCSF Well being. Sabari serves as an assistant professor within the Division of Medication at NYU Grossman Faculty of Medication and director of Excessive Reliability Group Initiatives at Perlmutter Most cancers Heart.
Sabari: Hiya, I’m Dr. Joshua Sabari. I’m a thoracic medical oncologist at NYU Langone Well being, Perlmutter Most cancers Heart in New York. I’m excited to be joined by Dr. Rita Mukhtar, a breast surgeon. Rita, please introduce your self.
Mukhtar: Thanks a lot, I’m pleased to be right here. As you talked about, my identify is Rita Mukhtar, and I’m a breast surgeon at UCSF. I additionally co-chair the native regional working group for the I-SPY2 trial, which is a neoadjuvant chemotherapy trial for sufferers with molecularly high-risk and low-risk breast most cancers. We heard a whole lot of data on the assembly concerning the position of ctDNA in breast most cancers, and it’s very thrilling; there’s a whole lot of curiosity in ctDNA to information systemic remedy and presumably for surveillance.
What I talked about was some thrilling knowledge the place we really checked out whether or not or not ctDNA might help us plan our surgical strategy for sufferers with breast most cancers. We checked out sufferers who had neoadjuvant chemotherapy, and ctDNA was measured earlier than chemotherapy, throughout and after. Then individuals went to the working room, and sometimes for breast most cancers surgical procedure, not less than a couple of lymph nodes are eliminated. If any of these lymph nodes nonetheless have tumor after chemotherapy, then sufferers endure axillary lymph node dissection, which includes eradicating the vast majority of lymph nodes within the axilla or armpit space, and that may trigger vital morbidity, akin to lymphedema.
What we actually wish to discover is a method to determine which sufferers are solely going to have perhaps one or two optimistic lymph nodes. Once you do this sentinel node biopsy, you’ve already gotten every thing out, and also you don’t must go on and take away any extra lymph nodes. We don’t have an effective way of figuring that out proper now, but it surely seems that ctDNA can predict whether or not or not somebody has a excessive likelihood or a low likelihood of getting many lymph nodes which might be nonetheless optimistic after chemotherapy. This can be a mannequin that we developed utilizing machine studying; it’s one thing that we’re going to must validate for positive. We seemed retrospectively at sufferers who’ve participated within the I-SPY trial, however we’re within the strategy of validating this additional.
These knowledge sort of open the door to the concept we could be checking ctDNA earlier than we go to the working room, and primarily based on the results of that, deciding if we’re going to do only a sentinel node biopsy or the total axillary dissection. The opposite thrilling factor is that we may additionally change the endpoints within the mannequin. Within the mannequin that we used, we actually predicted having a excessive nodal burden, however you can additionally predict having adverse nodes.
If we may use ctDNA to assist us be extremely assured that folks didn’t have any concerned lymph nodes, we perhaps may even omit all axillary surgical procedure in these high-risk sufferers who’re getting neoadjuvant chemotherapy.
Sabari: Thanks, Dr. Mukhtar, that was an outstanding presentation and really vital for guiding affected person care, notably within the working room. I do know within the lung most cancers house, we use a whole lot of ctDNA in each the early-stage and metastatic settings. How delicate are the assays that you simply’re utilizing in sufferers with breast most cancers?
Mukhtar: There’s been an enormous evolution in using ctDNA assays, beginning with the genotyping assays usually used within the metastatic setting. What we’re utilizing now are these MRD, or minimal residual illness, assays within the non-metastatic setting. These new era assays can detect tumor DNA within the blood down to 1 half per million.
Actually, assessing the sensitivity of the assay getting used is vital when evaluating the information and likewise when contemplating which assays to make use of going ahead, relying on the setting. We used the Signatera assay. The Signatera assay is a tumor-informed assay, that means the affected person’s major tumor is sequenced, and as much as 16 tumor-specific mutations can be utilized to create a probe to search for that circulating tumor DNA within the blood.
If sufferers have detection of not less than two of these mutations, we classify that as optimistic. We used optimistic or adverse because the endpoint or predictor in our research, however you can additionally take a look at the amount as a result of these are quantitative assays.
Sabari: That’s so vital. Thanks to your work; I’m trying ahead to seeing ongoing validation in order that it might change follow for our sufferers with breast most cancers. I’m joined once more by Dr. Rita Mukhtar, breast surgeon, and thanks for becoming a member of us and for collaborating and educating our CURE readers. Thanks.
Mukhtar: Thanks a lot. It’s a pleasure to be right here.
For extra information on most cancers updates, analysis and training, don’t overlook to subscribe to CURE®’s newsletters right here.
